
TriGemX Bio SPAC Merger: Late-Stage Migraine Bet Meets Cash Risk
TriGemX Bio is a clinical-stage biotech developing elismetrep for acute migraine, and it is going public through a merger with TCGX Acquisition Corp. The deal is expected to close in the first quarter of 2027, but the setup still hinges on redemptions, dilution, and whether Phase 3 execution stays on track.



